GLP-1 Drugs Linked to 30% Lower Breast Cancer Risk as Clinical Trial Launches
New data from 111,000+ women shows GLP-1 agonists cut breast cancer rates by 30%, spurring a major prevention trial.
Summary
A large retrospective study of over 111,000 women found that those who used GLP-1 agonist drugs for overweight or obesity had a 30% lower rate of breast cancer detected on imaging compared to non-users. The study, presented at the American Society of Clinical Oncology meeting, joins a growing body of evidence linking GLP-1 drugs like semaglutide to reduced cancer risk across multiple tumor types including leukemia, colon, liver, and endometrial cancers. Researchers are now preparing to launch a large prospective clinical trial within months, targeting high-risk women to formally test whether GLP-1 drugs can prevent breast cancer. While observational data cannot prove causation, the consistency of signals across cancer types is striking.
Detailed Summary
GLP-1 agonist drugs, widely used for weight loss and type 2 diabetes, are now generating serious interest as potential cancer prevention agents. A major study presented at the 2026 ASCO annual meeting found that women with overweight or obesity who used GLP-1 drugs had a 30% lower rate of breast cancer detected on imaging, adding momentum to plans for a formal prevention trial.
The retrospective cohort study analyzed data from 111,646 women aged 45–80 who underwent breast imaging between 2022 and 2025. After propensity matching, the GLP-1-exposed group showed a breast cancer rate of 1.62% versus 2.31% in unexposed women. Notably, even women with a prior breast cancer history showed lower recurrence rates when on GLP-1 therapy, 5.9% versus 9.2%.
Beyond breast cancer, parallel ASCO data showed GLP-1 use was associated with a 51% reduction in acute myelogenous leukemia risk in high-risk patients, with even steeper reductions in those with prior chemotherapy exposure. Signals were also reported across colon, lung, liver, endometrial cancers, and multiple myeloma, suggesting a potentially broad anti-cancer mechanism.
Researchers at Penn Medicine are now preparing to launch a large-scale prospective clinical trial within months. The trial will target overweight, non-obese women with elevated breast cancer risk, examining GLP-1 agonists for both primary and secondary cancer prevention as well as cardiovascular outcomes.
Important caveats apply. All current data is observational, meaning confounding factors could explain part of the benefit. The GLP-1-exposed group had higher rates of obesity, diabetes, and comorbidities, making propensity matching essential but imperfect. Whether the cancer benefit comes from weight loss, direct drug action, or metabolic improvements remains unknown and is a central question the upcoming trial aims to answer.
Key Findings
- Women on GLP-1 drugs had a 30% lower breast cancer rate versus non-users in a 111,000-person study.
- GLP-1 use linked to 51% reduced risk of acute myelogenous leukemia in high-risk patients.
- Prior chemotherapy patients on GLP-1s showed 74% lower AML risk and 71% lower ALL risk.
- A large prospective breast cancer prevention trial using GLP-1 drugs is set to launch within months.
- Cancer risk signals span multiple tumor types including colon, lung, liver, and endometrial cancers.
Methodology
This is a meeting coverage news report from MedPage Today based on data presented at ASCO 2026. The primary breast cancer study was a propensity-matched retrospective cohort of 111,646 women; leukemia data came from a separate retrospective cohort. Observational design limits causal conclusions.
Study Limitations
All findings are observational and cannot establish causation; confounding by indication is a major concern given GLP-1 users had more obesity and diabetes. The mechanism behind any cancer benefit is unknown. Results await peer-reviewed publication and confirmation in the planned prospective trial.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.